Chimeric Botulinum Neurotoxin BoNT/FA Potency and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current botulinum neurotoxins (BoNTs) used for therapeutic and cosmetic applications have limitations in terms of potency, duration of action, and safety margins, necessitating the development of BoNTs with altered properties for improved efficacy and safety.
Innovation Solution
Development of BoNT/FA, a chimeric toxin with altered properties, including a combination of BoNT/A1 receptor binding domain and BoNT/F5 light-chain domain, which exhibits enhanced potency, longer duration of action, and improved neuronal selectivity, offering a safer alternative to existing BoNTs like BoNT/B1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BoNTs (e.g., BoNT/A1, BoNT/B1) are used for therapeutic applications, then they can treat neuromuscular disorders, but their potency is limited and safety margins are narrow
Solution Approach 1:
The patent combines the heavy chain from BoNT/A1 with the light chain from BoNT/F5 to create a chimeric toxin BoNT/FA. This merging of components from different serotypes allows the toxin to inherit the high potency and neuronal selectivity of BoNT/A1 while acquiring the enhanced duration of action and improved safety profile of BoNT/F5, thereby resolving the contradiction between therapeutic efficacy and safety margin
Solution Approach 2:
The chimeric BoNT/FA represents a composite structure combining domains from different BoNT serotypes. The heavy chain domain (from BoNT/A1) provides receptor binding and translocation capabilities, while the light chain domain (from BoNT/F5) provides proteolytic activity with improved pharmacological properties. This composite approach enables the toxin to exhibit superior potency and safety compared to parent serotypes
2Productivity
If BoNT/A1 is used to achieve high potency, then it shows over 10-fold potency in human neurons, but it has shorter duration of action compared to BoNT/B1
Solution Approach 1:
The chimeric BoNT/FA merges the heavy chain of BoNT/A1 (responsible for high potency and neuronal selectivity) with the light chain of BoNT/F5 (responsible for longer duration of action). This combination allows the toxin to simultaneously achieve both high potency and extended duration of action, resolving the contradiction between these two parameters
3Duration of action of moving object
If BoNT/B1 is used to achieve longer duration of action, then it provides extended therapeutic effect, but it has reduced potency compared to BoNT/A1
Solution Approach 1:
By combining the BoNT/A1 heavy chain with the BoNT/F5 light chain, the chimeric BoNT/FA achieves both high potency (inherited from BoNT/A1) and long duration of action (inherited from BoNT/F5). This resolves the contradiction by creating a toxin that outperforms both parent serotypes in terms of potency while maintaining the extended duration of action
4Reliability
If higher doses of BoNTs are administered to improve therapeutic effect, then potency increases, but systemic symptoms and safety risks increase
Solution Approach 1:
The chimeric BoNT/FA changes the pharmacological parameters of the toxin by combining domains from different serotypes. This results in a toxin with enhanced potency and neuronal selectivity that achieves therapeutic effects at lower doses, thereby reducing systemic symptoms and improving the safety margin. The altered properties of BoNT/FA allow for more efficient target engagement with reduced off-target effects
Data Source
AI summary
The present disclosure relates to neurotoxins and uses thereof. In particular, provided herein are botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).